A drop in hormone therapy (HT) use in California was mirrored by a drop in breast cancer rates, with counties with the biggest decline in HT having a greater decline in cancer, according to the results of a large population-based study published in the Aug.
A drop in hormone therapy (HT) use in California was mirrored by a drop in breast cancer rates, with counties with the biggest decline in HT having a greater decline in cancer, according to the results of a large population-based study published in the Aug. 10 issue of the Journal of Clinical Oncology. At the same time, mammography rates remained stable, suggesting that the cancer decline may indeed have been due to a drop in HT use.
Anthony Robbins, MD, PhD, of the California Cancer Registry in Sacramento, Calif., and a colleague analyzed data from the registry that included nearly 3 million non-Hispanic white women aged 45 to 74. The researchers divided counties into three groups based on estrogen-progestin hormone therapy (EPHT) use in 2001. They then analyzed trends in the age-adjusted incidence of breast cancer in these counties compared with changes in hormone use.
Large regional differences were detected in the incidence of breast cancer and EPHT use between 2001 and 2004. Breast cancer incidence declined by 8.8% in counties with the smallest change in EPHT, by 13.9% in counties with an intermediate reduction, and by 22.6% in counties with the largest drop in EPHT.
Robbins AS, Clarke CA. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol. 2007;25:3437-3439.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More